Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Operating Expenses: 2016-2025

Historic Operating Expenses for Collegium Pharmaceutical (COLL) over the last 10 years, with Sep 2025 value amounting to $67.1 million.

  • Collegium Pharmaceutical's Operating Expenses rose 8.28% to $67.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $276.2 million, marking a year-over-year increase of 53.25%. This contributed to the annual value of $207.4 million for FY2024, which is 30.30% up from last year.
  • As of Q3 2025, Collegium Pharmaceutical's Operating Expenses stood at $67.1 million, which was down 8.45% from $73.3 million recorded in Q2 2025.
  • Collegium Pharmaceutical's 5-year Operating Expenses high stood at $75.6 million for Q1 2025, and its period low was $32.0 million during Q3 2021.
  • Its 3-year average for Operating Expenses is $53.0 million, with a median of $52.8 million in 2023.
  • Data for Collegium Pharmaceutical's Operating Expenses shows a peak YoY increase of 82.68% (in 2024) and a maximum YoY decrease of 20.45% (in 2024) over the last 5 years.
  • Quarterly analysis of 5 years shows Collegium Pharmaceutical's Operating Expenses stood at $32.8 million in 2021, then increased by 15.99% to $38.0 million in 2022, then dropped by 13.38% to $32.9 million in 2023, then soared by 82.68% to $60.2 million in 2024, then increased by 8.28% to $67.1 million in 2025.
  • Its Operating Expenses stands at $67.1 million for Q3 2025, versus $73.3 million for Q2 2025 and $75.6 million for Q1 2025.